- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02928926
Cerebral Haemodynamics in Stroke Thrombolysis Study (CHIST) (CHIST)
Cerebral Haemodynamics in Stroke Thrombolysis (CHIST) Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
In the UK alone, approximate 100,000 people suffer a stroke each year. Improved management of stroke patients not only reduces morbidity and mortality, but also reduces the cost of long term social care. The brain has control systems (i.e. cerebral autoregulation) to maintain blood flow to the brain, over a relatively wide blood pressure range. Cerebral Autoregulation can be described as static, reflecting the integrity of such mechanisms over time, or dynamic, occurring in response to sudden fluctuations in perfusion pressure. When blood pressure drops, small arteries increase in size to restore flow levels, and when blood pressure rises, they narrow to protect the most delicate blood vessels. it is known that sudden decompensated blood pressure changes can occur after stroke, this could result in brain bleeding and swelling where there is a reduced blood flow to the brain.
It is known that the clotbusting agent (Alteplase), the main effective treatment used in the acute stroke can improve blood flow in already blocked arteries in 50% of patients. However, as it is a powerful drug that dissolves clots, there is a risk that it may cause bleeding (haemorrhage) in the body. This is most serious when it occurs in the brain, either in the region of the stroke or another part of the brain, which if serious, could lead to greater disability or even death. To date, there has been little information regarding the natural history and prognostic significance of impaired cerebral autoregulation during and following restoration of brain blood flow (reperfusion), especially those who received clotbusting agent (Alteplase). There are also conflicting findings between animal and human models. There is evidence from an animal study that restoration of blood flow in postischaemic brain arteries may result in generation of free oxygen radicals, leading to further cerebral autoregulation impairment. Furthermore, there is evidence from animal models that clotbusting agent (Alteplase) may exhibit additional blood vessel toxic effect and therefore, further impair cerebral autoregulation. However, such findings could not be reproduced in the human settings. To date, there is only one small study looking at cerebral autoregulation in 14 acute ischaemic stroke patients 8 days after clotbusting treatment, there have not been studies to assess blood flow regulation at the initiation and completion of the clotbusting treatment.
Cerebral autoregulation can be assessed noninvasively by the use of Trans Cranial Doppler (TCD). This means using ultrasound probes over both sides of the head to measure changes in blood flow in one of the main brain arteries (the middle cerebral artery) in response to beat to beat changes dynamic cerebral autoregulation. However, the use of TCD may be limited by the absence of brain window and/or occlusion of the middle cerebral artery in the acute ischaemic stroke patients. Therefore, it is important to consider alternative sites to the middle cerebral artery to assess brain blood flow regulation, and our group has previously researched the use of the main neck artery (the internal carotid artery) site. In a healthy control population, brain blood flow regulation index (autoregulation index) estimated from the internal carotid artery is not statistically different from the middle cerebral artery. However, such comparisons have not been made in the acute ischaemic stroke population. This research will use noninvasive technique of Trans Cranial Doppler to look at blood flow regulation in the brain (cerebral autoregulation) in clotbusting therapy (thrombolysis) treated acute ischaemic stroke (AIS) patients at the initiation and completion of thrombolysis, and during acute, subacute and chronic phase post stroke onset, compared to those AIS patients who have similar age, sex and blood pressure but not treated with thrombolysis. This study will provide important data regarding peri-thrombolysis blood pressure management, an important and common clinical dilemma.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
-
Leicester, United Kingdom, LE1 5WW
- University Hosptial of Leicester NHS Trust
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Informed patient consent or personal consultee declaration form
- Male or female, aged 18 years or above
- Able (in the Investigator's opinion) and willing to comply with all study requirements
- Willing to allow his or her General Practitioner (GP) to be notified of participation in the study
rtPA Stroke Patient-specific Inclusion Criteria:
- Who meet the criteria for thrombolytic therapy with intravenous rtPA
Non- rtPA Stroke Patient-specific Inclusion Criteria:
- Clinical diagnosis of stroke within 6 hours of onset but not eligible for rtPA therapy, and the reason recorded
Exclusion Criteria:
- Male or Female, aged under 18 years
- Unable (in the Investigator's opinion) or unwilling to comply with any study requirements
- Significant pre-stroke dependency (premorbid Modified Rankin Score >3)
- Co-morbidity with anticipated life expectancy less than 3 months
- Current participation in another investigational drug trial
rtPA Stroke Patient-specific Exclusion Criteria:
- Participants who do not meet the criteria for thrombolytic therapy with intravenous rtPA
Non-rtPA Stroke Patient-specific Exclusion Criteria:
- Clinical diagnosis of stroke greater than 6 hours from onset
- Having had a resolved transient ischaemic attack (TIA) (i.e. neurological symptoms completely resolved or rapidly improving within 1 hour of onset)
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Thrombolysis
Acute ischaemic stroke patients who receive intravenous thrombolysis
|
patients who are eligible with intravenous thrombolysis or admitted within the timeframe to receive thrombolysis but not eligible due to other reasons
|
non thrombolysis
Acute ischaemic stroke patients who admitted to the hospital within the timeframe for intravenous thrombolysis but contraindicate to receive intravenous thrombolysis
|
patients who are eligible with intravenous thrombolysis or admitted within the timeframe to receive thrombolysis but not eligible due to other reasons
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change of the autoregulation index
Time Frame: During intravenous thrombolysis infusion, 1 week and 3 months post stroke symptoms onset
|
Change of the autoregulation index during intravenous thrombolysis infusion, 1 week and 3 months post stroke symptoms onset
|
During intravenous thrombolysis infusion, 1 week and 3 months post stroke symptoms onset
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change of the dynamic cerebral autoregulation
Time Frame: During intravenous thrombolysis infusion, 1 week and 3 months post stroke symptom onset
|
Using transcranial Doppler, beat to beat blood pressure monitoring, to calculate the change of the dynamic cerebral autoregulation, during intravenous thrombolysis infusion, 1 week and 3 months post stroke symptom onset
|
During intravenous thrombolysis infusion, 1 week and 3 months post stroke symptom onset
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Thompson G Robinson, MD FRCP, University of Leicester
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0542
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ischaemic Stroke
-
West China HospitalNational Natural Science Foundation of China; Chengdu University of Traditional... and other collaboratorsCompletedSevere Ischaemic Stroke | Malignant Ischaemic StrokeChina
-
AstraZenecaCompletedAcute Ischaemic Stroke | Transient Ischaemic AttackBelgium, France, Italy, Spain, Sweden, Thailand, Germany, Korea, Republic of, Brazil, Hungary, India, Mexico, Vietnam, China, Taiwan, Hong Kong, Slovakia, Australia, Poland, Saudi Arabia, Ukraine, Canada, Russian Federation, Bulgaria, R... and more
-
AstraZenecaCompletedAcute Ischaemic Stroke | Transient Ischaemic AttackSweden, United States, Australia, Brazil, Bulgaria, France, Italy, Korea, Republic of, Mexico, Peru, Poland, Russian Federation, Spain, Turkey, Vietnam, Germany, Philippines, China, Hungary, Romania, Ukraine, Hong Kong, Argentina, Bel... and more
-
Singapore General HospitalSingapore University of Technology and DesignCompletedIschaemic StrokeSingapore
-
BayerCompletedMyocardial Infarction | Unstable Angina | Angina | Ischaemic Heart Disease | Stroke (Including Ischaemic Stroke and Transient Ischaemic Attack)Germany, United Kingdom
-
Institut National de la Santé Et de la Recherche...Fondation de l'AvenirUnknown
-
Boehringer IngelheimCompleted
-
NHS Greater Glasgow and ClydeUniversity of GlasgowCompletedIschaemic StrokeUnited Kingdom
-
NHS Greater Glasgow and ClydeUniversity of Glasgow; Aurum Biosciences LtdUnknown
-
Xiangya Hospital of Central South UniversityRecruiting
Clinical Trials on intravenous thrombolysis
-
Centre Hospitalier Universitaire VaudoisThe University of Texas Health Science Center, Houston; Charite University,... and other collaboratorsCompletedArterial Occlusive Diseases | Ischemic Stroke | Vertebrobasilar Insufficiency | Vertebral Artery IschemiaSwitzerland
-
University Hospital Inselspital, BerneUniversity of Zurich; University Hospital, Geneva; University Hospital, Basel... and other collaboratorsCompletedIschemic StrokeSwitzerland
-
Zhengzhou YuanRecruiting
-
Xiangya Hospital of Central South UniversityRecruiting
-
The First Affiliated Hospital of University of...Not yet recruiting
-
Acticor BiotechActive, not recruitingAcute Ischemic StrokeUnited States, Germany
-
Second Affiliated Hospital, School of Medicine,...RecruitingStroke, Acute IschemicChina
-
Changhai HospitalAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA); Wu Jieping... and other collaboratorsCompletedIschemic Stroke | Thrombosis | Large Vessel Occlusion | Thrombectomy | AlteplaseChina
-
Mayo ClinicTerminatedStroke | Ischemic StrokeUnited States
-
Acticor BiotechCompleted